Per-patient prescription drug spending increased by 32.4 percent at hospitals that recently enrolled in the 340B Drug Pricing Program, revealed a new Berkeley Research Group (BRG) study funded by the Pharmaceutical Research and Manufacturers of America (PhRMA).
There seems to be no end in sight for the current partial government shutdown, the third since the beginning of the Trump administration. For the vast majority of the federal government’s public health efforts, though, it’s business as usual.
Pharmaceutical companies are ringing in the new year by raising the price of hundreds of drugs, with Allergan PLC setting the pace with increases of nearly 10% on more than two dozen products, according to a new analysis.
The Community Oncology Alliance (COA) recently submitted formal comments to the Centers for Medicare and Medicaid Services (CMS) regarding the Medicare Program International Pricing Index Model for Medicare Part B Drugs pre-proposed rule, also known as the IPI Model.
The Community Oncology Alliance (COA) has submitted formal comments to the Centers for Medicare and Medicaid Services (CMS) regarding the Medicare Program International Index Model for Medicare Part B Drugs, commonly known as the IPI Model.
A Republican-led White House and Senate, a Democratic House majority and the American public usually have their eyes on different health-related priorities — but heading into 2019, all sights are set squarely on the rising cost of prescription drugs.
The Federal Courts gave the America Hospital Association and 340B covered entities a late Christmas present and in doing so may have dealt a blow to the Trump Administration’s initiatives aimed at controlling or reducing drug prices.
American Oncology Network, LLC (AON) is pleased to announce that Zangmeister Cancer Center (ZCC), a leading community oncology/hematology practice in Columbus, Ohio, partnered with AON on January 1st, 2019. AON is an alliance of physicians and veteran healthcare leaders uniting to ensure the long-term success of community oncology.
Opposes IPI as Proposed Because of Serious Concerns About Patient Impact and Legality but Working on Alternatives Releases Research Analysis on Myth of Physician Incentives in Part B System The Community Oncology Alliance (COA) recently submitted formal comments to the Centers for Medicare and Medicaid Services (CMS) regarding the Medicare Program International Pricing Index Model